Chris J. Packard

41.8k citations

209 papers · 19.1k indexed · 11 hit papers · h-index 68

Impact in

Endocrinology, Diabetes and Metabolism top 0.05%
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diet, Metabolism, and Disease
Cardiology and Cardiovascular Medicine top 0.2%
- Lipid metabolism and disorders

Papers in

Endocrinology, Diabetes and Metabolism 102
- Diabetes, Cardiovascular Risks, and Lipoproteins 94
Cancer Research 44
- Cancer, Lipids, and Metabolism 38

Co-authors: James Shepherd Ian Ford Muriel Caslake Naveed Sattar Allan Gaw Marja‐Riitta Taskinen Stuart M. Cobbe Peter W. Macfarlane
Journals: Atherosclerosis (23 papers)Journal of Lipid Research (11 papers)Current Opinion in Lipidology (9 papers)European Heart Journal (8 papers)Circulation (6 papers)
Partner nations: United Kingdom United States Sweden

In The Last Decade

Chris J. Packard

206 papers receiving 18.4k citations

Hit Papers

11 papers align trajectories log scale

Lipoprotein(a) Is Markedly More Atherogenic Than LDL 2024 · 98 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Journal of the American College of Cardiology
2023 European Heart Journal
2022 Nature Reviews Cardiology
2019 JAMA
2007 The Lancet
2006 Diabetologia
2003 Circulation
2002 The Lancet
2002 Diabetes
2001 Circulation
2000 New England Journal of Medicine

Peers

Countries citing papers authored by Chris J. Packard

Since Specialization

Citations

This map shows the geographic impact of Chris J. Packard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris J. Packard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris J. Packard more than expected).

Fields of papers citing papers by Chris J. Packard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris J. Packard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris J. Packard. The network helps show where Chris J. Packard may publish in the future.

Co-authors

The 25 scholars most cited alongside Chris J. Packard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chris J. Packard Line = papers co-authored together Chris J. Packard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease European Heart Journal ·Jan Borén, Chris J. Packard, Børge G. Nordestgaard, Alberico L. Catapano	2025	3
2	Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3 silencing and predicts clinically relevant coronary heart disease event reductions European Journal of Preventive Cardiology ·Elias Björnson, Chris J. Packard, Martin Adiels, Nicholas J. Leeper, Jennifer Hellawell, Anders Gummesson, Steven E. Nissen, Jan Borén	2025	2
3	Lipoprotein(a) Is Markedly More Atherogenic Than LDL Journal of the American College of Cardiology ·Elias Björnson, Martin Adiels, Marja‐Riitta Taskinen, Stephen Burgess, M. John Chapman, Chris J. Packard, Jan Borén Hit paper breakdown →	2024	98
4	Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study European Heart Journal ·Elias Björnson, Martin Adiels, Marja‐Riitta Taskinen, Stephen Burgess, Aidin Rawshani, Jan Borén, Chris J. Packard Hit paper breakdown →	2023	97
5	Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations JCI Insight ·Marja‐Riitta Taskinen, Elias Björnson, Niina Matikainen, Sanni Söderlund, Joel Rämö, Mari Ainola, Antti Hakkarainen, Carina Sihlbom, Annika Thorsell, Linda Andersson, Per‐Olof Bergh, Marcus Henricsson, Stefano Romeo, Martin Adiels, Samuli Ripatti, Markku Laakso, Chris J. Packard, Jan Borén	2022	22
6	Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes Arteriosclerosis Thrombosis and Vascular Biology ·Marja‐Riitta Taskinen, Elias Björnson, Juhani Kahri, Sanni Söderlund, Niina Matikainen, Kimmo Porthan, Mari Ainola, Antti Hakkarainen, Nina Lundbom, Susan Landau, J. Fuchs, Annika Thorsell, Florian Kronenberg, Linda Andersson, Martin Adiels, Chris J. Packard, Jan Borén	2020	19
7	Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans JCI Insight ·Jan Borén, Martin Adiels, Elias Björnson, Niina Matikainen, Sanni Söderlund, Joel Rämö, Marcus Ståhlman, Pietari Ripatti, Samuli Ripatti, Aarno Palotie, Rosellina Margherita Mancina, Antti Hakkarainen, Stefano Romeo, Chris J. Packard, Marja‐Riitta Taskinen	2020	50
8	Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence Current Atherosclerosis Reports ·Matthew M.Y. Lee, Naveed Sattar, John J.V. McMurray, Chris J. Packard	2019	66
9	Association of oily fish intake, sex, age, BMI andAPOEgenotype with plasma long-chainn-3 fatty acid composition British Journal Of Nutrition ·Helena L. Fisk, Michael A. Irvine, Elizabeth A. Miles, Georg Lietz, John C. Mathers, Chris J. Packard, Christopher K. Armah, Barbara Kofler, Peter J. Curtis, Anne Marie Minihane, Philip C. Calder	2018	14
10	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above Circulation ·Antonio J. Vallejo‐Vaz, Michele Robertson, Alberico L. Catapano, Gerald F. Watts, John J.P. Kastelein, Chris J. Packard, Ian Ford, Kausik K. Ray	2017	118
11	Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy Circulation ·Ian Ford, Heather Murray, Colin McCowan, Chris J. Packard	2016	169
12	New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory Vascular Pharmacology ·Chris J. Packard, William S. Weintraub, Ulrich Laufs	2015	21
13	Socioeconomic Deprivation and Cortical Morphology Psychosomatic Medicine ·Rajeev Krishnadas, John McLean, G. David Batty, Harry Burns, Kevin A. Deans, Ian Ford, Alex McConnachie, Jennifer McLean, Keith Millar, Naveed Sattar, Paul G. Shiels, Carol Tannahill, Yoga N. Velupillai, Chris J. Packard, Jonathan Cavanagh	2013	42
14	Early life socioeconomic status, chronic physiological stress and hippocampal N-acetyl aspartate concentrations Behavioural Brain Research ·John McLean, (unknown), Rajeev Krishnadas, G. David Batty, Harry Burns, Kevin A. Deans, Ian Ford, Alex McConnachie, Agnes McGinty, Jennifer McLean, Keith Millar, Naveed Sattar, Paul G. Shiels, Carol Tannahill, Yoga N. Velupillai, Chris J. Packard, Barrie Condon, Donald M. Hadley, Jonathan Cavanagh	2012	20
15	Soluble ST2 Associates with Diabetes but Not Established Cardiovascular Risk Factors: A New Inflammatory Pathway of Relevance to Diabetes? PLoS ONE ·Ashley M. Miller, David Purves, Alex McConnachie, Darren L. Asquith, G. David Batty, Harry Burns, Jonathan Cavanagh, Ian Ford, Jennifer McLean, Chris J. Packard, Paul G. Shiels, Helen Turner, Yoga N. Velupillai, Kevin A. Deans, Paul Welsh, Iain B. McInnes, Naveed Sattar	2012	56
16	Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies The Lancet ·(unknown), Alexander Thompson, Pei Gao, Lia Orfei, Sarah Watson, Emanuele Di Angelantonio, Stephen Kaptoge, Christie M. Ballantyne, Christopher P. Cannon, Michael H. Criqui, Mary Cushman, Albert Hofman, Chris J. Packard, Isnin Fajar, Rory Collins	2010	481
17	Effect of Pravastatin in People with Diabetes and Chronic Kidney Disease Journal of the American Society of Nephrology ·Marcello Tonelli, Anthony Keech, 真澄松嶋, Frank M. Sacks, Andrew Tonkin, Chris J. Packard, Marc A. Pfeffer, John Simes, Chris Isles, Curt D. Furberg, Malcolm West, Tim Craven, Gary C. Curhan	2005	107
18	Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease Current Opinion in Lipidology ·Muriel Caslake, Chris J. Packard	2003	98
19	UK Food Standards Agency <I>cis</I>-monounsaturated fatty acid workshop report British Journal Of Nutrition ·Peter Sanderson, Jason M. R. Gill, Chris J. Packard, T. A. B. Sanders, Bengt Vessby, Christine M. Williams	2002	2
20	At what level of coronary heart disease risk should a statin be prescribed? Current Opinion in Lipidology ·Allan Gaw, Chris J. Packard	2000	11

About Chris J. Packard

Chris J. Packard is a scholar working on Endocrinology, Diabetes and Metabolism, Cancer Research, Surgery, Cardiology and Cardiovascular Medicine and Epidemiology, having authored 209 papers that have together received 19.1k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (112 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (94 papers), Cancer, Lipids, and Metabolism (38 papers), Lipid metabolism and disorders (32 papers), Health Systems, Economic Evaluations, Quality of Life (18 papers), Adipokines, Inflammation, and Metabolic Diseases (18 papers), Liver Disease Diagnosis and Treatment (17 papers) and Atherosclerosis and Cardiovascular Diseases (15 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (7.4k citations), Cardiology and Cardiovascular Medicine (4.8k citations), Surgery (8.1k citations), Cancer Research (2.4k citations) and Epidemiology (4.2k citations). Chris J. Packard has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include James Shepherd, Ian Ford, Muriel Caslake, Naveed Sattar, Allan Gaw, Marja‐Riitta Taskinen, Stuart M. Cobbe, Peter W. Macfarlane, Jan Borén and J. Shepherd. Their work appears in journals such as Atherosclerosis, Journal of Lipid Research, Current Opinion in Lipidology, European Heart Journal and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact